CHICAGO — About 80 percent of patients with moderate to severe psoriasis saw their disease completely or almost completely cleared with a new drug called ixekizumab, according to three large, long-term clinical trials led by Northwestern Medicine.
Read more at Northwestern Medicine
Learn more at National Psoriasis Foundation Act Now
